Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a research report report published on Tuesday morning,Benzinga reports. Chardan Capital currently has a $25.00 price target on the stock.

A number of other analysts also recently weighed in on LXEO. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Lexeo Therapeutics presently has an average rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Trading Up 8.6 %

Shares of NASDAQ LXEO opened at $4.44 on Tuesday. The company’s 50 day simple moving average is $4.12 and its 200 day simple moving average is $6.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50. The firm has a market capitalization of $146.81 million, a P/E ratio of -1.41 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.09. On average, analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LXEO. Wellington Management Group LLP boosted its position in shares of Lexeo Therapeutics by 48.3% during the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after buying an additional 25,089 shares during the period. Woodline Partners LP boosted its position in Lexeo Therapeutics by 0.8% during the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after acquiring an additional 6,730 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Lexeo Therapeutics by 41.2% during the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after acquiring an additional 350,000 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Lexeo Therapeutics by 102.5% in the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after purchasing an additional 379,828 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Lexeo Therapeutics by 282.5% in the fourth quarter. Millennium Management LLC now owns 141,951 shares of the company’s stock valued at $934,000 after purchasing an additional 104,837 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.